XETRA - Delayed Quote EUR

Sartorius Stedim Biotech S.A. (56S1.DE)

Compare
201.50
-4.50
(-2.18%)
As of 9:04:07 AM GMT+1. Market Open.

Research Analysis

Revenue vs. Earnings

Revenue 655.4M
Earnings 25.5M
Q4'23
Q1'24
Q2'24
Q3'24
0
200M
400M
600M
 

Analyst Price Targets

Earnings Estimate

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts --------
Avg. Estimate 0000
Low Estimate 0000
High Estimate 0000
Year Ago EPS --------

Revenue Estimate

Currency in EUR Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
No. of Analysts 4--1312
Avg. Estimate 722.22M--2.77B2.99B
Low Estimate 706.5M--2.7B2.91B
High Estimate 732.74M--2.83B3.11B
Year Ago Sales 706.8M--2.78B2.77B
Sales Growth (year/est) 2.18%---0.36%8.29%

EPS Trend

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Current Estimate 0000
7 Days Ago 0000
30 Days Ago 0000
60 Days Ago 0000
90 Days Ago 0000

EPS Revisions

Currency in USD Current Qtr. (Dec 2024)Next Qtr. (Mar 2025)Current Year (2024)Next Year (2025)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
56S1.DE --------
S&P 500 8.58%11.41%13.97%13.43%

Upgrades & Downgrades

Downgrade Societe Generale: Buy to Hold 10/1/2021

Related Tickers